Dr. Arash Rezazadeh Kalebasty

Jevtana's Toxicity Profile Makes It a Good Option in Metastatic Prostate Cancer

October 09, 2019

When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.